InMed Pharmaceuticals has developed a proprietary process capable of extracting all 90+ cannabinoids in a laboratory setting.
Read our Medical Marijuana Compound Report for Free Today!
The next big innovation is unfolding now and it’s already creating a wave of multi-millionaire investors in the process

13x13x1 READ MORE
Read the Investors Guide To Newly Emerging Marijuana Markets 
Dear Seed Investor, 

NetworkNewsWire today released an article looking at the economic impact that InMed's proprietary biosynthesis could have on the cannabis industry, while looking at the process of other large industry players. 

The article looks at the current industry process of extraction, the challenges it faces, and how InMed's process could affect it. 

"InMed’s innovative process targets significant cost savings as well as enhanced production, purification and quality control compared to existing grow-harvest-extract-purify methods employed by other companies." 

Here's an excerpt below, but we recommend reading the full article

NetworkNewsWire Editorial Coverage: According to a recent Haywood Securities research report, the value of the cannabidiol (CBD) market is expected to hit $2.1 billion by 2020.

CBD is just one compound out of more than 90 found within the cannabis plant, though.

While many companies with an interest in medicinal marijuana pursue various avenues to extract cannabinoids, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) has developed a proprietary process capable of extracting all 90+ cannabinoids in a laboratory setting, eliminating most of the costly requirements that typically come with cannabinoid extraction.

To understand the value of this process, it helps to take a look at the methods utilized by other industry players such as GW Pharmaceuticals (NASDAQ: GWPH) and Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), as well as the challenges of high-volume cannabis cultivators like Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF) and Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF).

Fueled by mounting increases in consumer demand and expanding legalization, the race is on to find a cost effective method of extracting medicinal-grade cannabinoids.

To glean pharmaceutically-viable cannabinoid compounds, cannabis must first be physically grown in quantity.

Then, the cannabinoids are extracted and processed in an attempt to meet the exacting purity levels required by regulatory standards.

Sourcing cannabinoids naturally requires planting, growing, harvesting, extracting and purifying huge quantities of plants.

Breath of Life Pharma, recently featured in a Rolling Stone article, had to dedicate one million square feet of cannabis cultivation space in order to produce enough raw flower for its extraction business.

Producing compounds from plant extracts is time consuming and expensive, and, despite cultivating thousands of tons of cannabis, most companies in this arena can only produce a couple of the 90+ cannabinoids present in the plant. Many cannabinoids are found only in trace amounts and will never be accessible or economically feasible with current extraction methods.

Click to read full article

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

High Profits, 

The Seed Investor
Please see full disclaimers on the website applicable to all content provided by TSI, wherever published or re-published:

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
32x32x1   32x32x2
9375 E Shea Blvd Ste 100
Scottsdale 85260
©2019, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.